The Small Molecule Screening and Synthesis Facility (SMSSF) provides UWCCC members with access to high throughput screening (HTS) instrumentation, chemical and RNAi libraries, synthetic chemistry, computational molecular modeling, virtual screening and expert staff. These are all critical activities for early stage discovery of new anti-cancer drugs. By providing infrastructure and expertise that is not available in individual member laboratories, the SMSSF enables UWCCC members to initiate and implement projects focused on the discovery and development of new anti-cancer agents, as well as the characterization of new drug targets. During the past five years, 50 members from seven of the eight Scientific Programs in the UWCCC have used the SMSSF for their research. The data generated at SMSSF has contributed to over 47 publications from UWCCC members and more than 40 funded grants. During the past five years the SMSSF successfully added three new services: screening of a human genome-wide RNAi library, synthetic chemistry for producing analogs or for scale-up and virtual screening.

Public Health Relevance

New safe and effective drugs are needed to treat human cancers. UWCCC members are able to initiate novel drug discovery projects because the Small Molecule Screening and Synthesis Facility provides access to infrastructure and expertise in drug discovery and to chemical and RNAi libraries that are not available in individual academic laboratories.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762770
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$120,671
Indirect Cost
$59,443
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Guerrero, Natalie; Small, Alissa L; Schwei, Rebecca J et al. (2018) Informing physician strategies to overcome language barriers in encounters with pediatric patients. Patient Educ Couns 101:653-658
Chapelin, Fanny; Capitini, Christian M; Ahrens, Eric T (2018) Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. J Immunother Cancer 6:105
Ni, Dalong; Ferreira, Carolina A; Barnhart, Todd E et al. (2018) Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc 140:14971-14979
Chang, Julie E; Carmichael, Lakeesha L; Kim, KyungMann et al. (2018) VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk 18:e61-e67
Pearson, Hannah E; Iida, Mari; Orbuch, Rachel A et al. (2018) Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. Mol Cancer Ther 17:204-214
Mora-Pinzon, Maria C; Trentham-Dietz, Amy; Gangnon, Ronald E et al. (2018) Urinary Magnesium and Other Elements in Relation to Mammographic Breast Density, a Measure of Breast Cancer Risk. Nutr Cancer 70:441-446
DuBenske, Lori L; Schrager, Sarina B; Hitchcock, Mary E et al. (2018) Key Elements of Mammography Shared Decision-Making: a Scoping Review of the Literature. J Gen Intern Med 33:1805-1814
Wang, Dongdong; Shi, Ruohong; Zhou, Jiajia et al. (2018) Photo-Enhanced Singlet Oxygen Generation of Prussian Blue-Based Nanocatalyst for Augmented Photodynamic Therapy. iScience 9:14-26
Erbe, Amy K; Wang, Wei; Carmichael, Lakeesha et al. (2018) Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res 24:189-196
Eckers, Jaimee C; Swick, Adam D; Kimple, Randall J (2018) Identity Crisis - Rigor and Reproducibility in Human Cell Lines. Radiat Res 189:551-552

Showing the most recent 10 out of 1528 publications